Colorectal cancer symptoms are easy to explain away — a little rectal bleeding, a few weeks of looser stools, a tiredness that feels like the price of a busy season. That is precisely why screening matters so much here. Colorectal cancer is one of the very few cancers that screening can prevent outright rather than simply catch early, because most of these tumors start as a small growth called a polyp, and removing that polyp stops the cancer from ever forming. In this article you will learn which symptoms deserve attention, why screening in the United States now begins at age 45, how the available tests genuinely compare, what the rise in cases among adults under 50 does and does not mean, and where routine lab results fit in.
Screening does not just find colorectal cancer — it prevents it
Most cancers can only be caught early. Colorectal cancer is different. The great majority of these tumors develop slowly from a benign growth on the inner lining of the bowel, usually over eight to ten years or more. If that growth is found and removed while it is still a polyp, the cancer that would have grown out of it never exists. A colonoscopy that removes a polyp is not only a test; it is a treatment. Stool-based tests work through the same logic: they remove nothing themselves, but a positive result routes you to a colonoscopy where polyps can be taken out on the spot.
The Centers for Disease Control and Prevention recommends that adults at average risk begin screening at age 45 and continue through 75, with a shared decision between 76 and 85. That starting age dropped from 50, and the change was driven by data rather than caution.
Colorectal cancer symptoms worth taking seriously
Early tumors frequently cause nothing at all, which is the whole reason screening exists. When colorectal cancer symptoms do appear, they fall into a short and recognizable list.
The core warning signs
- Rectal bleeding, whether bright red on the paper or dark blood mixed into the stool.
- A change in bowel habit that lasts more than a few weeks — new constipation, new diarrhea, or an alternating pattern.
- Stools that become persistently narrow or pencil-thin.
- A feeling that the bowel has not emptied completely, even right after going.
- Cramping, gas pain or abdominal discomfort that keeps returning in the same place.
- Unexplained weight loss, meaning weight that falls without a change in diet or activity.
- Fatigue or breathlessness on mild exertion, which often reflects anemia rather than the tumor itself.
None of these findings is specific to cancer. Bright red bleeding far more often comes from swollen veins around the anus, and many readers arrive here after reading about hemorrhoids and their symptoms. The point is not that every sign is sinister, but that anything lasting several weeks deserves an explanation from a clinician rather than a self-diagnosis.
When anemia is the only sign
A slow-bleeding tumor can drip a very small amount of blood into the bowel each day without ever turning the stool visibly red. Over months that steady loss drains the body’s iron stores, producing iron-deficiency anemia, and in a striking number of people it is the first and only abnormality — found on a routine blood panel ordered for something else. This is why an unexplained low hemoglobin in an adult is a red flag rather than a nuisance. Clinicians usually confirm the pattern by ordering a complete blood count panel and then measuring iron stores directly with a ferritin blood test. A low ferritin with a low hemoglobin, in an adult with no obvious source of blood loss, is one of the classic presentations that leads to a colonoscopy. Readers who want the broader picture can also review the causes of anemia and their treatments.
Why the right side of the colon behaves differently
Where a tumor sits changes which colorectal cancer symptoms appear first. Tumors on the right side of the colon sit far upstream, so blood they release is broken down before stool reaches the rectum and is invisible to the eye; the bowel there is wider and its contents more liquid, so narrowing comes late. Right-sided tumors therefore tend to present as fatigue and iron-deficiency anemia with almost no bowel complaints. Left-sided and rectal tumors sit in a narrower tube with more formed stool, so they declare themselves earlier with visible bleeding, narrow stools and changed bowel habits.
Why more adults under 50 are being diagnosed
The rise among younger adults is real, has been measured in dozens of countries, and has not stopped. In the United States the share of colorectal cancers occurring in people under 55 roughly doubled between the mid-1990s and 2019, making this the most rapidly increasing early-onset cancer in the country, ahead of other digestive cancers such as pancreatic cancer and its warning signs. Rates in older adults have been falling over the same period, largely thanks to screening.
Perspective matters. The disease remains uncommon in absolute terms before 50, and most young adults with rectal bleeding do not have cancer. Obesity, type 2 diabetes, sedentary time and diet are all under investigation as contributors, and none of them explains the whole trend.
What a young adult should not accept
The practical consequence is a communication problem, not a panic problem. Young adults with rectal bleeding are frequently told — by themselves, by friends, and sometimes by a clinician — that it is obviously hemorrhoids. Often it is. But that is a conclusion which should follow an examination, not replace one. If you are under 50 and have bleeding, a persistent change in bowel habit, unexplained weight loss or unexplained anemia, ask directly whether the bowel has been looked at. Family history matters too: a parent, sibling or child diagnosed with colorectal cancer or advanced polyps usually means starting screening earlier than 45. Inflammatory bowel disease raises risk as well, which is one reason people managing Crohn’s disease and its treatments or living with ulcerative colitis and its symptoms are screened on a different schedule.
The screening menu, with honest trade-offs
There is no single correct test. Each option trades convenience against thoroughness.
| Test | Typical interval | What it involves | The honest trade-off |
|---|---|---|---|
| Colonoscopy | Every 10 years | Bowel prep, sedation, a camera through the whole colon | The only test that removes polyps during the exam, so it can prevent cancer. Costs a day and a prep, with a small risk of bleeding or perforation. |
| Fecal immunochemical test (FIT) | Every year | One stool sample collected at home, no prep, no diet change | Cheap, easy and effective when repeated every year. Detects hidden blood in the stool, not polyps, so it misses growths that are not bleeding. |
| Stool DNA test (multi-target) | Every 3 years | A whole stool sample mailed to a laboratory | Finds more early cancers than FIT alone, but raises more false alarms and so more normal colonoscopies. |
| CT colonography | Every 5 years | A CT scan of the colon, still requiring bowel prep | No sedation and no scope, but nothing can be removed, so anything found sends you to colonoscopy anyway. |
| Blood-based screening test | Every 3 years | A standard blood draw looking for tumor DNA in the circulation | By far the easiest to complete. Good at finding cancer already present, poor at finding the precancerous polyps screening is meant to catch. |
The rule that decides everything
Any positive result on a non-colonoscopy test must be followed by a colonoscopy. Not a repeat stool test, not a wait-and-see, not a different blood test. A stool or blood test that flags a problem has done its entire job; the diagnostic step still has to happen. This is where screening programs most often break down. In United States health systems studied through a national colorectal cancer control program, follow-up colonoscopy after an abnormal stool test was completed by fewer than half of people on average, and the figure varied enormously between systems. A screening test you complete but never act on provides close to no protection. If you are unsure what a stool report is telling you, BloodSense can also explain a stool test report in plain language. If you send off a stool kit or give a blood sample, plan in advance for what happens if it comes back positive.
The best test is the one that actually gets done
Clinicians repeat this line because it is true. An annual FIT performed faithfully for twenty years protects a person far better than a colonoscopy they keep postponing. If bowel prep, cost, time off work or fear of sedation is the barrier, a yearly stool test is a legitimate choice rather than a compromise. The only wrong option is the one where nothing happens.
When to see a doctor
- Any rectal bleeding at any age, even if you have a known history of hemorrhoids — a known cause does not rule out a second one.
- A change in bowel habit persisting beyond three to four weeks.
- Abdominal pain that keeps recurring in the same location.
- Unexplained weight loss of more than a few pounds.
- An unexplained low hemoglobin or low ferritin, particularly in a man of any age or a woman past menopause.
- Reaching age 45 without having started screening, or reaching your earlier family-history threshold.
Sudden severe abdominal pain, vomiting with an inability to pass stool or gas, and heavy bleeding are emergencies needing same-day care.
How colorectal cancer is diagnosed and staged
Colonoscopy remains the diagnostic test. If a suspicious area is seen, a biopsy is taken and read by a pathologist, and confirmation is followed by imaging — usually CT of the chest, abdomen and pelvis, plus a pelvic MRI for rectal tumors. Stage runs from I, confined to the bowel wall, to IV, spread to distant organs, and it drives treatment more than any other factor. The liver is the most frequent site of spread, which is why readers sometimes confuse this disease with liver cancer and its symptoms; a tumor that started in the bowel and travelled to the liver is still colorectal cancer.
Tumor testing that changes decisions
Every colorectal tumor should be tested for mismatch repair status, reported as MMR or MSI. Mismatch repair is the cell’s spell-checker for DNA; when it fails, the tumor accumulates enormous numbers of mutations that make it highly visible to the immune system, and those tumors respond remarkably well to immunotherapy. This single test can redirect the entire treatment plan.
The same test serves a second purpose. A deficient result can be the first clue to Lynch syndrome, an inherited condition that raises the lifetime risk of colorectal, uterine and several other cancers; identifying it changes surveillance for the patient and opens genetic testing for the whole family. That is why universal tumor testing is now standard. Advanced tumors are additionally tested for KRAS, NRAS and BRAF mutations, which determine whether certain targeted drugs will work at all, and sidedness is weighed too, since right-sided and left-sided tumors respond differently to the same targeted therapies.
What CEA is, and what it is not
Carcinoembryonic antigen, or CEA, is a blood protein often elevated in colorectal cancer. It is not a screening test and should never be used as one: levels are normal in many people who have cancer and raised in many who do not, including smokers and people with benign liver or bowel conditions. Its value comes after a diagnosis — a baseline is measured before treatment, and a rising level afterwards can be the earliest signal that disease has returned. If you have seen this marker on a report, you can read the full explanation of CEA blood test results.
How colorectal cancer is treated today
Surgery is the foundation for disease that has not spread. The surgeon removes the affected segment of bowel with its nearby lymph nodes, and in most cases the two ends are rejoined; a permanent stoma is far less common than people fear and mainly concerns tumors very low in the rectum. Chemotherapy afterwards is added when the risk of hidden residual disease is meaningful, typically in stage III and selected stage II colon cancer. For rectal cancer, chemotherapy and radiation are now often given before surgery, an approach that has improved outcomes.
For advanced disease, treatment follows the tumor’s molecular profile: immunotherapy first for mismatch repair deficient tumors, and targeted antibodies matched to KRAS, NRAS and BRAF status. Liver metastases are no longer automatically inoperable, and a meaningful number of people are cured after removal of a limited number of liver deposits. Survival in metastatic disease has improved substantially over the past two decades.
Lowering your risk
Screening carries by far the strongest evidence, but everyday factors contribute. Regular physical activity, a healthy weight, limited alcohol, not smoking, enough fiber, and moderate red and processed meat all shift risk modestly downward. None of this replaces screening. If you also have persistent digestive symptoms, your clinician may check bowel inflammation with a fecal calprotectin test before deciding what to do next.
Latest scientific advances
Research has moved quickly over the past three years. Here is what the most relevant recent work found, in plain terms.
The American Cancer Society confirmed age 45 and assessed the newer tests
A 2026 guideline update reviewed the newer molecular screening options — a stool RNA test, a next-generation stool DNA test and a blood-based DNA test — and reaffirmed that average-risk adults should start at 45 and continue to 75. What this means for you: the starting age is settled, and the newer tests are additions to the menu rather than replacements for the established ones.
Blood tests are convenient but weak at finding polyps
Two large validation studies, one from 2024 and one from 2025, tested blood samples for tumor DNA in thousands of adults who then had a colonoscopy for comparison. Both found the same pattern: the blood test detected the large majority of colorectal cancers already present, but only a small minority of advanced precancerous polyps. What this means for you: a blood test is a genuine option if the alternative is no screening at all, but it is much better at catching cancer than at preventing it, because it mostly cannot see the growths a colonoscopy would remove.
Follow-up after an abnormal stool test is the weak link
An analysis of health systems in a national screening program between 2019 and 2023 tracked what happened after abnormal stool tests. On average, fewer than half of those patients completed the follow-up colonoscopy, and completion varied widely between systems. What this means for you: treat a positive stool result as an appointment to book immediately, and ask your clinic how it tracks results — this step, not the test itself, is where most protection is lost.
The rise in early-onset disease is confirmed across countries
An analysis of cancer registry data covering 50 countries and territories found colorectal cancer incidence rising in adults under 50 in many nations while rates in older adults were stable or falling, and a 2025 review reported that colorectal cancer is the most rapidly increasing early-onset gastrointestinal cancer worldwide. What this means for you: the trend is well documented, so colorectal cancer symptoms in a young adult should be investigated rather than assumed benign. It does not mean the disease is common before 50 — it remains uncommon in absolute numbers.
Diet and metabolic health are being examined as contributors
A 2026 analysis of a long-running study of United States nurses — a cohort, meaning a group followed over many years — found that women eating the most ultraprocessed food had a higher risk of the precancerous polyps that precede early-onset colorectal cancer. A separate 2025 review argued that obesity and type 2 diabetes may drive part of the increase in younger adults. What this means for you: these findings suggest an association rather than proof of cause and remain preliminary, so they support general dietary advice rather than any drastic change.
Molecular profiling continues to reshape treatment
A 2024 overview described how routine tumor testing for mismatch repair status and for KRAS, NRAS and BRAF mutations, together with circulating tumor DNA measured after surgery, is steadily individualizing treatment. What this means for you: if you or a relative is diagnosed, asking whether the tumor has been fully profiled is a useful question.
Glossary
| Term | Definition |
|---|---|
| Polyp | A small growth on the inner lining of the bowel. Most are harmless, but some types slowly turn into cancer over years, which is why they are removed. |
| Colonoscopy | An examination of the entire colon with a flexible camera, performed under sedation. Polyps found during the exam can be removed immediately. |
| FIT | Fecal immunochemical test. A home stool test that detects human blood in stool using antibodies. It requires no bowel prep and no diet change. |
| Iron-deficiency anemia | A shortage of red blood cells caused by depleted iron stores. Slow bleeding in the bowel is a common cause in adults. |
| Ferritin | A blood protein that reflects how much iron the body has stored. A low value is the most reliable sign that iron stores are exhausted. |
| MMR and MSI | Mismatch repair and microsatellite instability. Laboratory tests on the tumor that show whether the cell’s DNA repair system is working. A faulty system predicts a strong response to immunotherapy. |
| Lynch syndrome | An inherited condition that raises the lifetime risk of colorectal, uterine and several other cancers. It is often first suspected from tumor testing. |
| CEA | Carcinoembryonic antigen. A blood protein used to monitor colorectal cancer after diagnosis. It is not suitable for screening healthy people. |
| Staging | The process of describing how far a cancer has spread, from stage I confined to the bowel wall to stage IV involving distant organs. |
| Neoadjuvant therapy | Treatment such as chemotherapy or radiation given before surgery, to shrink a tumor and improve the outcome of the operation. |
Frequently asked questions
How did people know they had colon cancer?
The most commonly reported first clue is rectal bleeding or blood mixed into the stool, followed by a bowel habit that changed and stayed changed for several weeks. A large number of people, though, had no digestive symptoms at all and were investigated because a routine blood test showed unexplained iron-deficiency anemia. A smaller group had no symptoms whatsoever and were diagnosed purely through screening, which is the situation with the best outcomes. The pattern that recurs in patient accounts is not a dramatic symptom but a mild one that persisted and was initially dismissed.
Can colorectal cancer be cured?
Yes, frequently. Cancer confined to the bowel wall is cured by surgery in the large majority of cases, and disease that has reached nearby lymph nodes is still curable with surgery followed by chemotherapy. Even some cancer that has spread to the liver can be cured when the deposits are limited and removable. Outcomes depend heavily on stage at diagnosis, which is the entire argument for screening: cancers found by screening are, on average, found much earlier than cancers found because of symptoms.
Is a blood test enough to screen for colon cancer?
A blood-based screening test is an approved option, and it is far better than skipping screening. But the evidence shows it detects only a small share of the advanced precancerous polyps that a colonoscopy would find and remove, so it is much stronger at detecting existing cancer than at preventing cancer from developing. If you are able and willing to do a colonoscopy or an annual stool test, those remain the more protective choices. Whichever you choose, a positive result always requires a colonoscopy.
How often should I be screened?
It depends on the test and on your risk. At average risk, colonoscopy is generally repeated every ten years, FIT every year, stool DNA testing every three years, CT colonography every five years and blood-based testing every three years. Anyone who has had polyps removed, has inflammatory bowel disease, has a close relative diagnosed with colorectal cancer, or carries an inherited syndrome follows a shorter, individualized interval decided with their clinician.
Does colorectal cancer run in families?
Often, though most cases occur in people with no family history. Having a parent, sibling or child diagnosed with colorectal cancer or with advanced polyps roughly doubles risk and usually means starting screening earlier than 45 — commonly ten years before the age at which the relative was diagnosed. A minority of cases come from a clearly inherited condition such as Lynch syndrome or familial adenomatous polyposis, and these are worth identifying because they change surveillance for an entire family.
Can hemorrhoids be mistaken for colorectal cancer?
The two can produce identical bleeding, which is exactly the problem. Hemorrhoids are common, colorectal cancer is not, so most bleeding turns out to be benign. But having hemorrhoids does not protect you from also having something else, and a visible hemorrhoid is not proof that it is the source of the blood. The safe approach is to have bleeding assessed rather than assumed, especially if it is new, if it persists, or if it is accompanied by a change in bowel habit, weight loss or fatigue.
Sources
- Centers for Disease Control and Prevention — Screening for Colorectal Cancer, 2025 — CDC colorectal cancer screening
- MedlinePlus, National Library of Medicine — Colorectal Cancer, 2025 — MedlinePlus colorectal cancer topic
- Mayo Clinic — Colon cancer: symptoms and causes, 2024 — Mayo Clinic colon cancer overview
- Colorectal cancer screening: an update to the American Cancer Society guideline — CA: A Cancer Journal for Clinicians, 2026 — doi.org/10.3322/caac.70083
- A cell-free DNA blood-based test for colorectal cancer screening — New England Journal of Medicine, 2024 — doi.org/10.1056/NEJMoa2304714
- Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer — JAMA, 2025 — doi.org/10.1001/jama.2025.7515
- Subramanian S, Tangka FKL, Hoover S, et al. — Optimizing tracking and completion of follow-up colonoscopy after abnormal stool tests at health systems participating in the Centers for Disease Control and Prevention’s Colorectal Cancer Control Program — Cancer Causes and Control, 2024 — doi.org/10.1007/s10552-024-01898-w
- Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data — The Lancet Oncology, 2025 — doi.org/10.1016/S1470-2045(24)00600-4
- Early-onset gastrointestinal cancers: a review — JAMA, 2025 — doi.org/10.1001/jama.2025.10218
- Ultraprocessed food consumption and risk of early-onset colorectal cancer precursors among women — JAMA Oncology, 2026 — doi.org/10.1001/jamaoncol.2025.4777
- Early-onset colorectal cancer as an emerging disease of metabolic dysregulation — Nature Reviews Endocrinology, 2025 — doi.org/10.1038/s41574-025-01159-z
- Colorectal cancer — The Lancet, 2024 — doi.org/10.1016/S0140-6736(24)00360-X
- Colorectal cancer statistics, 2023 — CA: A Cancer Journal for Clinicians, 2023 — doi.org/10.3322/caac.21772
Further reading
- Fecal occult blood test results explained
- Visible blood in stool test results
- Hemoglobin blood test results
- Stool color and what it indicates
- Serum iron test results
Understand your lab results with BloodSense
Colorectal cancer is discovered surprisingly often through ordinary laboratory results rather than dramatic symptoms — a stool test that detects hidden blood, or a blood panel showing low hemoglobin and depleted iron stores. Those numbers are hard to read on your own, and a single value out of range rarely means what people fear. BloodSense turns your blood, urine and stool results into clear, plain-language explanations so you can see what has actually changed and what is worth raising with your doctor. It helps you understand your results; it does not diagnose, and it does not replace medical care.
